Pancreatic Cancer Research

ResearcherWashington University in St. LouisNo recent work listed

Tim F. Greten

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0806-2535; OpenAlex author ID A5057000867. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2013: 3 papers · 2014: 3 papers · 2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper

Papers 9

  1. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-19-3624↗
  2. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Co-author DOI 10.1200/jco.2014.57.4244↗
  3. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis fr… Co-author DOI 10.3109/0284186x.2015.1034877↗
  4. Myeloid-derived suppressor cells in pancreatic cancer: more than a hidden barrier for antitumour immunity? Co-author DOI 10.1136/gutjnl-2014-306790↗
  5. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. Co-author DOI 10.1186/1471-2407-14-624↗
  6. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from … Co-author DOI 10.1200/jco.2013.53.6995↗
  7. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-P… Co-author DOI 10.1038/bjc.2012.495↗
  8. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Last author DOI 10.1093/annonc/mdt166↗
  9. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of … Co-author DOI 10.1136/gutjnl-2012-302759↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Austin G. Duffy · 2 shared papers, 2013–2020 · strength 0.13
  2. Michael Geißler · 4 shared papers, 2013–2015 · strength 0.13
  3. Volker Heinemann · 4 shared papers, 2013–2015 · strength 0.13
  4. Stefan Hubert Boeck · 4 shared papers, 2013–2015 · strength 0.13
  5. Jonathan Matthew Hernandez · 1 shared paper, 2020 · strength 0.09
  6. Freddy E. Escorcia · 1 shared paper, 2020 · strength 0.09
  7. Changqing Xie · 1 shared paper, 2020 · strength 0.09
  8. Jeremy L. Davis · 1 shared paper, 2020 · strength 0.09
  9. Michael Haas · 2 shared papers, 2014–2015 · strength 0.07
  10. Stephan Krüger · 2 shared papers, 2014–2015 · strength 0.07
  11. Susanna Hegewisch‐Becker · 2 shared papers, 2013–2015 · strength 0.07
  12. Dirk Waldschmidt · 2 shared papers, 2013–2015 · strength 0.07
  13. Osama E. Rahma · 1 shared paper, 2013 · strength 0.05
  14. Dominik Paul Modest · 1 shared paper, 2015 · strength 0.04
  15. Deirdre Jill Cohen · 1 shared paper, 2015 · strength 0.04
  16. Dung Thi Le · 1 shared paper, 2015 · strength 0.04
  17. Gregory M. Springett · 1 shared paper, 2015 · strength 0.04
  18. Jennifer N. Uram · 1 shared paper, 2015 · strength 0.04
  19. Todd S. Crocenzi · 1 shared paper, 2015 · strength 0.04
  20. Dirk G. Brockstedt · 1 shared paper, 2015 · strength 0.04
  21. Herbert J. Zeh · 1 shared paper, 2015 · strength 0.04
  22. Elizabeth M. Jaffee · 1 shared paper, 2015 · strength 0.04
  23. Michael Andrew Morse · 1 shared paper, 2015 · strength 0.04
  24. Eric R. Lutz · 1 shared paper, 2015 · strength 0.04
  25. Robert Lance Fine · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.